<DOC>
	<DOCNO>NCT02093897</DOCNO>
	<brief_summary>This international , multicenter , open-label study ass efficacy , safety , pharmacokinetic ( PK ) profile rVIII-SingleChain pediatric patient severe hemophilia A . A minimum 25 previously treat subject â‰¥ 6 &lt; 12 year age least 25 subject &lt; 6 year age undergone &gt; 50 exposure day ( EDs ) previous Factor VIII ( FVIII ) product plan enrol . Subjects assign either on-demand prophylaxis treatment regimen receive rVIII-SingleChain dose determine investigator . Hemostatic efficacy assess subject/caregiver investigator ass overall efficacy 4-point scale .</brief_summary>
	<brief_title>Pharmacokinetic , Efficacy , Safety Study Recombinant Factor VIII Single Chain ( rVIII-SingleChain ) Children With Severe Hemophilia A</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>Diagnosis severe hemophilia A defined &lt; 1 % Factor VIII ( FVIII ) concentration ( FVIII : C ) document medical record , Males &lt; 12 year age , Subjects receive &gt; 50 EDs FVIII product , Prior PK data ( least incremental recovery halflife ) previous FVIII exposure subject participate PK part Investigator believe subject willing able adhere protocol requirement . Investigator believe subject 's parent ( ) legally acceptable representative ( ) / willing able adhere protocol requirement . Any history current FVIII inhibitor Use Investigational Medical Product ( IMP ) within 30 day prior first rVIIISingleChain administration , Administration cryoprecipitate , whole blood plasma within 30 day prior administration rVIIISingleChain , Known hypersensitivity ( allergic reaction anaphylaxis ) FVIII product hamster protein , Subject currently receive IV immunomodulating agent immunoglobulin chronic systemic corticosteroid treatment , Subject serum aspartate aminotransferase ( AST ) serum alanine aminotransferase ( ALT ) value &gt; 5 time ( x ) upper limit normal ( ULN ) Screening , Subjects serum creatinine value &gt; 2 x ULN Screening , Evidence thrombosis , include deep vein thrombosis , stroke , pulmonary embolism , myocardial infarction arterial embolus within 3 month Day 1 , Experienced lifethreatening bleed episode major surgery orthopedic surgical procedure 3 month rVIIISingleChain administration .</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>11 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>